US4816561A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biologically active polypeptides
Assignee: REGENICS Corp
•
Filing: 1985-09-17
•
Granted: 1989-03-28
•
Expires: 2005-09-17
Abstract
Abstract Novel biologically active polypeptides, including a new class of transforming growth factor (TGF) polypeptides, which exhibit cell growth promoting properties are disclosed, as well as a process for isolating the TGF polypeptides from both human and murine cell lines in homogeneous form. Also disclosed are antigenic oligopeptides derived from the TGF polypeptides and antibodies raised therefrom which have application in the detection and treatment of malignancies and oligipeptides which have the ability to bind with cellular growth factor receptors and thus to interfere with transformation of certain cell lines into a cancerous state. Compositions and methods based on the disclosed peptides for detection and treatment of cancer and other proliferative diseases and for cell or tissue growth associated treatment, e.g., wound healing, ulcer therapy and bone loss are also described.
Inventors
- 👤 George J. Todaro
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 02:01
CPC Classifications
C; C07; C07K; C07K7/00; C07K7/04; C07K7/08; C07K14/00; C07K14/435; C07K14/475; C07K14/495; C07K16/00; C07K16/18; C07K16/22; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/12
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
34 words
A polypeptide transforming growth factor or oligomers thereof of the formula: ##STR7## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr.
Claim 2
Dependent Claim
34 words
A polypeptide transforming growth factor or oligomers thereof of the formula: ##STR7## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr.
Claim 3
Dependent Claim
20 words
The polypeptide according to claim 1, wherein R is Asp, R' is Phe, R" is Ser and R'" is Phe.
Claim 4
Dependent Claim
20 words
The polypeptide according to claim 1, wherein R is Lys, R' is Tyr, R" is Phe and R'" is Tyr.
Claim 5
Dependent Claim
26 words
A polypeptide growth factor containing one or more of the following peptide fragments: A. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-Ser-His-Thr-Gln-Tyr-Cys-Phe-His-Gly-Thr-Cys B. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-Ser-His-Thr-Gln-Phe-Cys-Phe-His-Gly-Thr-Cys C. Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala-Cys-Val-Cys-His-Ser-Gly D. Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala E. Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala-Cys-Val-Cys-His-Ser-Gly and F. Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala.
Claim 6
Dependent Claim
26 words
A polypeptide growth factor containing one or more of the following peptide fragments: A. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-Ser-His-Thr-Gln-Tyr-Cys-Phe-His-Gly-Thr-Cys B. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-Ser-His-Thr-Gln-Phe-Cys-Phe-His-Gly-Thr-Cys C. Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala-Cys-Val-Cys-His-Ser-Gly D. Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala E. Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala-Cys-Val-Cys-His-Ser-Gly and F. Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala.
Claim 7
Dependent Claim
17 words
The polypeptide growth factor according to claim 4, wherein the polypeptide contains peptide fragments A and C.
Claim 8
Dependent Claim
17 words
The polypeptide growth factor according to claim 4, wherein the polypeptide contains peptide fragments B and C.
Claim 9
Dependent Claim
18 words
The polypeptide growth factor according to claim 4, wherein the polypeptide contains peptide fragments B, C, and D.
Claim 10
Dependent Claim
34 words
An antigenic oligopeptide selected from the sequences consisting of: A. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-His-Thr B. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-His-Thr C. Arg-Phe-Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala D. Arg-Tyr-Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala E. Cys-His-Ser-Gly-Phe-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala F. Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala G. Arg-Phe-Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala H. Arg-Tyr-Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala I. Cys-His-Ser-Gly-Phe-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-ASp-Leu-Leu-Ala J. Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala K. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-Ser-His-Thr and L. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-Ser-His-Thr.
Claim 11
Dependent Claim
34 words
An antigenic oligopeptide selected from the sequences consisting of: A. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-His-Thr B. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-His-Thr C. Arg-Phe-Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala D. Arg-Tyr-Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala E. Cys-His-Ser-Gly-Phe-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala F. Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala G. Arg-Phe-Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala H. Arg-Tyr-Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala I. Cys-His-Ser-Gly-Phe-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-ASp-Leu-Leu-Ala J. Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala K. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-Ser-His-Thr and L. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-Ser-His-Thr.
Claim 12
Dependent Claim
20 words
The polypeptide according to claim 1, wherein R is Asp, R' is Phe, R" is Phe and R'" is Tyr.
Claim 13
Dependent Claim
33 words
A polypeptide transforming factor or oligomers thereof of the formula: ##STR8## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr.
Claim 14
Dependent Claim
33 words
A polypeptide transforming factor or oligomers thereof of the formula: ##STR8## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr.
Claim 15
Dependent Claim
20 words
The polypeptide according to claim 10, wherein R is Asp, R' is Phe, R" is Phe and R'" is Tyr.
Claim 16
Dependent Claim
17 words
The polypeptide growth factor according to claim 4, wherein the polypeptide contains peptide fragments B and E.
References Cited (Backward Citations)
US4287185A
Cited
US4428942A
Cited
US4443434A
Cited
WO1984001106A1
Cited
JPS59216058A
Cited
US4485101A
Cited
WO1985002198A1
Cited
EP0154434A1
Cited
US4742003A
Cited
US4749683A
Cited
US4686283A
Cited
US4650787A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-03-27 | 1992-09-26 | 1993-03-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-03-27 | 1996-09-26 | 1997-03-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-03-27 | 2000-09-26 | 2001-03-28 | $7700.00 | Window Closed / Lapsed |